Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8011 to 8025 of 8901 results

  1. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655. 

    Withdrawn guidance

  2. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

    This guidance has been updated and replaced by NICE technology appraisal guidance 713.

    Withdrawn guidance

  3. Venetoclax for treating chronic lymphocytic leukaemia (TA487)

    This guidance has been updated and replaced by NICE technology appraisal guidance 796.

    Withdrawn guidance

  4. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

    This guidance has been updated and replaced by NICE technology appraisal guidance 653.

    Withdrawn guidance

  5. Human growth hormone for the treatment growth failure in children (TA42)

    This guidance has been updated and replaced by NICE technology appraisal guidance 188. 

    Withdrawn guidance

  6. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

    Withdrawn guidance

  7. Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.

    Withdrawn guidance

  8. IQoro for stroke-related dysphagia (MIB175)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.

    Withdrawn advice

  9. Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke (MIB141)

    This advice has been updated and replaced by NICE healthtech guidance 553.

    Withdrawn advice

  10. Curos disinfecting cap for needleless connectors (MIB143)

    This advice has been updated and replaced by NICE medical technologies guidance 44.

    Withdrawn advice

  11. UroShield for preventing catheter-associated urinary tract infections (MIB191)

    This advice has been updated and replaced by NICE healthtech guidance 620.

    Withdrawn advice

  12. Alpha-Stim AID for anxiety (MIB193)

    This advice has been updated and replaced by NICE healthtech guidance 570.

    Withdrawn advice

  13. DyeVert for reducing contrast media in coronary and peripheral angiography (MIB196)

    This advice has been updated and replaced by NICE healthtech guidance 594.

    Withdrawn advice

  14. Leukomed Sorbact for preventing surgical site infection (MIB197)

    This advice has been updated and replaced by NICE healthtech guidance 567.

    Withdrawn advice

  15. Prontosan for acute and chronic wounds (MIB220)

    This advice has been updated and replaced by NICE healthtech guidance 616.

    Withdrawn advice